2025
How well do disease-specific studies and WHO-CHOICE cost estimates align? Example of estimating cost per episode of diarrhoea and respiratory syncytial virus in 128 low-income and middle-income countries
Li X, Bilcke J, Asare E, Wenger C, Kwon J, Bont L, Beutels P, Pitzer V. How well do disease-specific studies and WHO-CHOICE cost estimates align? Example of estimating cost per episode of diarrhoea and respiratory syncytial virus in 128 low-income and middle-income countries. BMJ Global Health 2025, 10: e016784. PMID: 40850784, PMCID: PMC12382583, DOI: 10.1136/bmjgh-2024-016784.Peer-Reviewed Original ResearchMeSH KeywordsCost-Benefit AnalysisDeveloping CountriesDiarrheaHealth Care CostsHumansRespiratory Syncytial Virus InfectionsRotavirus InfectionsWorld Health OrganizationConceptsRespiratory syncytial virusRSV-related diseaseWHO-CHOICE estimatesEpisodes of diarrheaLower middle-incomeWHO-CHOICELow-incomeUpper middle-incomeSyncytial virusRSV studiesInpatient costsMiddle-incomeDiarrhoeal diseaseEconomic evaluationCost studiesMiddle-income countriesDisease-specific diagnosisRSV-specificDisease-specific costsCost-effectiveness studiesDisease-specific studiesOutpatient costsEmpirical studiesDiarrheaCountry-specific data
2023
Cost-effectiveness analysis of typhoid conjugate vaccines in an outbreak setting: a modeling study
Phillips M, Antillon M, Bilcke J, Bar-Zeev N, Limani F, Debellut F, Pecenka C, Neuzil K, Gordon M, Thindwa D, Paltiel A, Yaesoubi R, Pitzer V. Cost-effectiveness analysis of typhoid conjugate vaccines in an outbreak setting: a modeling study. BMC Infectious Diseases 2023, 23: 143. PMID: 36890448, PMCID: PMC9993384, DOI: 10.1186/s12879-023-08105-2.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentCost-Benefit AnalysisCost-Effectiveness AnalysisHumansTyphoid FeverTyphoid-Paratyphoid VaccinesVaccines, ConjugateConceptsTyphoid Conjugate VaccineRoutine vaccinationReactive vaccinationVaccination strategiesOutbreak settingsMultidrug-resistant Salmonella typhiQueen Elizabeth Central HospitalTyphoid fever epidemicYears of ageMonths of ageCost-effectiveness analysisWorld Health OrganizationConjugate vaccineCentral HospitalRoutine immunizationVaccine deploymentPreventive vaccinationVaccinationTyphoid feverCost-effective strategyAge 15Health OrganizationFever epidemicAntimicrobial resistanceOutbreak definitions
2022
Comparison of model predictions of typhoid conjugate vaccine public health impact and cost-effectiveness
Burrows H, Antillón M, Gauld J, Kim J, Mogasale V, Ryckman T, Andrews J, Lo N, Pitzer V. Comparison of model predictions of typhoid conjugate vaccine public health impact and cost-effectiveness. Vaccine 2022, 41: 965-975. PMID: 36586741, PMCID: PMC9880559, DOI: 10.1016/j.vaccine.2022.12.032.Peer-Reviewed Original ResearchMeSH KeywordsCost-Benefit AnalysisHumansPublic HealthTyphoid FeverTyphoid-Paratyphoid VaccinesVaccines, ConjugateConceptsIncremental cost-effectiveness ratioRoutine vaccinationVaccine impactPublic health impactOne-time catchPotential public health impactHigh-incidence settingsTyphoid fever casesCost-effectiveness ratioMonths of ageHealth impactsModel-predicted outcomesPrimary outcomeChronic carriersIncidence settingsSymptomatic casesVaccine introductionEndemic settingsVaccine deploymentFever casesVaccinationTyphoid casesIncremental costTyphoid transmissionMonthsPredicting the long-term impact of rotavirus vaccination in 112 countries from 2006 to 2034: A transmission modeling analysis
Kraay A, Steele M, Baker J, Hall E, Deshpande A, Saidzosa B, Mukaratirwa A, Boula A, Mpabalwani E, Kiulia N, Tsolenyanu E, Enweronu-Laryea C, Abebe A, Beyene B, Tefera M, Willilo R, Batmunkh N, Pastore R, Mwenda J, Antoni S, Cohen A, Pitzer V, Lopman B. Predicting the long-term impact of rotavirus vaccination in 112 countries from 2006 to 2034: A transmission modeling analysis. Vaccine 2022, 40: 6631-6639. PMID: 36210251, PMCID: PMC10351612, DOI: 10.1016/j.vaccine.2022.09.072.Peer-Reviewed Original ResearchMeSH KeywordsCost-Benefit AnalysisGastroenteritisHumansInfantRotavirusRotavirus InfectionsRotavirus VaccinesVaccinationConceptsRotavirus vaccinationRotavirus positivityVaccine introductionOne-dose scheduleTwo-dose seriesRotavirus burdenRotavirus casesRotavirus gastroenteritisHospital admissionMiddle-income countriesVaccine impactVaccinated individualsLong-term impactMortality burdenPercent reductionVaccinationLife yearsIndirect protectionLow-income countriesLong-term magnitudePositivityDeathBurdenYearsIntroduction Data
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply